Clinical trials: Ductal Carcinoma
Thyroid Neoplasia, Well-Differentiated Thyroid Cancer
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
This study will evaluate the clinical response and safety of ultrasound guided percutaneous thermal ablation of lymph node metastases from thyroid carcinoma as an alternative to surgical treatment.
- Conditions
- Thyroid Neoplasia, Well-Differentiated Thyroid Cancer, Medullary Thyroid Cancer, Lymph Node Metastases
- Trial name
- NCT04522570
- Testing
- Laser ablation, Cryoablation, Radiofrequency ablation
- Where
- Brazil
- Volunteers
- 84 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Breast Ductal Carcinoma in Situ
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
Although the results obtained from ECOG E5194 cohort 1 (criteria: mammographically detected low- or intermediate-grade DCIS, measuring less than 2.5 cm with margins ≥ 3 mm) and RTOG 9804 trial (the same enrolled…
- Trial name
- NCT04046159
- Testing
- Low-dose tamoxifen, Whole breast radiotherapy
- Where
- Taiwan
- Volunteers
- 810 people
- Sponsor
- National Taiwan University Hospital
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer
- Trial name
- NCT03906331
- Testing
- Selpercatinib
- Where
- 64 sites in United States, Australia and 11 more
- Sponsor
- Eli Lilly and Company
Breast Cancer, Breast Neoplasms, Male
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
The purposes of this study are to determine whether pemetrexed can help patients with metastatic (cancer that has spread to other parts of the body) breast cancer, to determine any side effects that may be associated with the…
- Conditions
- Breast Cancer, Breast Neoplasms, Male, Carcinoma, Ductal
- Trial name
- NCT00106002
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Fatigue
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
RATIONALE: Paced breathing may be an effective way to reduce the number and severity of hot flashes in women who have survived breast cancer.
- Conditions
- Breast Cancer, Fatigue, Hot Flashes, Sleep Disorders
- Trial name
- NCT00569166
- Testing
- Paced breathing (15 min once daily, 6 breaths/min), Paced breathing (15 min twice daily, 6 breaths/min), Paced breathing (10 min once daily, 14 breaths/min)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma in Situ
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)
- Trial name
- NORDIS (NCT03909282)
- Testing
- Lumpectomy, Partial breast irradiation prior to surgery
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 305 (NCT07621718)
- Testing
- Zoldonrasib, Oxaliplatin, Leucovorin (Calcium Folinate)
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 670 people
- Sponsor
- Revolution Medicines, Inc.
Head and Neck Cancer
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100828
- Testing
- irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations.
- Conditions
- Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
- Trial name
- NCT04042831
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Academic and Community Cancer Research United
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
This study is the study of the combination of PEGPH20 and Pembrolizumab (MK-3475) for patients with previously treated Hyaluronan High (HA-high) metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- NCT03634332
- Testing
- PEGPH20, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pancreatic Cancer Research Team
Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
This clinical trial studies mammography and targeted ultrasound with or without whole-breast ultrasound or contrast-enhanced magnetic resonance imaging (MRI) in finding out the extent of disease before surgery in patients with…
- Conditions
- Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT02587663
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Southern California
Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC )
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.
- Conditions
- Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma
- Trial name
- NCT07914764
- Testing
- Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Soft Tissue Sarcomas, Thyroid Cancer
11C-Acetate PET/CT Non-FDG-Avid Tumors
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor.
- Conditions
- Soft Tissue Sarcomas, Thyroid Cancer, Lung Cancer, Indolent Lymphoma
- Trial name
- NCT00687778
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
PDAC
68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma
Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitutes a major proportion of cells within the tumor microenvironment, especially in primary pancreatic ductal carcinoma…
- Trial name
- NCT05275985
- Testing
- 68Ga-FAPI Positron Emission Tomography-Computed Tomography
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT01100489
- Testing
- external beam radiation therapy, questionnaire administration, therapeutic conventional surgery
- Where
- 3 sites in United States
- Sponsor
- Case Comprehensive Cancer Center